Braun Stacey Associates Inc. Buys 4,827 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Braun Stacey Associates Inc. increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,012 shares of the biotechnology company’s stock after acquiring an additional 4,827 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Sarepta Therapeutics were worth $12,865,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Capital International Investors increased its stake in Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after purchasing an additional 76,032 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after acquiring an additional 37,940 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Sarepta Therapeutics by 26.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after acquiring an additional 120,535 shares during the last quarter. Finally, abrdn plc boosted its holdings in Sarepta Therapeutics by 30.7% during the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock worth $53,935,000 after acquiring an additional 101,253 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 4.2 %

Shares of SRPT opened at $104.54 on Monday. The firm has a market cap of $9.99 billion, a P/E ratio of 83.63 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1 year low of $78.67 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a 50 day simple moving average of $123.72 and a two-hundred day simple moving average of $132.38.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of research analyst reports. StockNews.com raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $205.00 price target on shares of Sarepta Therapeutics in a report on Thursday, November 7th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Finally, Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Buy” and a consensus price target of $181.33.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.